Lupin Limited’s recent settlements give investors as much reason to cheer as to be concerned. A $253.2m provision for a settlement related to antitrust class actions filed in the Northern District of California regarding Glumetza (metformin) led the company to report a fiscal second quarter loss of INR14.7bn ($196.4m).
A group of Glumetza purchasers had alleged that Lupin agreed to delay the launch of its generic by four years in exchange for $3m in cash and an agreement by the originator parties not to market an authorized generic to compete with the Indian company, which subsequently saw a price hike of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?